Company

Portfolio Data

Back to Company Search

CHROMOLOGIC LLC

Address

1225 S SHAMROCK AVE
MONROVIA, CA, 91016-4244
USA

View website

UEI: D9EVNTKKWLF3

Number of Employees: 35

HUBZone Owned: No

Woman Owned: No

Socially and Economically Disadvantaged: No

SBIR/STTR Involvement

Year of first award: 2007

Phase I Awards

Phase II Awards

50.85%

Conversion Rate

$10,825,030

Phase I Dollars

$31,309,282

Phase II Dollars

$42,134,313

Total Awarded

Awards

Up to 10 of the most recent awards are being displayed. To view all of this company's awards, visit the Award Data search page.

Membrane-based AWE Device (MAWED)

Amount: $249,907 Topic: HR0011SB20244-02

In order toĀmeet DARPA need, ChromoLogic LLC (CL) proposes developing a Membrane-based AWE Device (MAWED) to ensure a consistent supply of potable water as a distributable system. Unlike traditional cooling-condensing and absorption/desorption methods, MAWED uses an energy-efficient vapor capture and passive condensing approach, combined with a compact, high-surface-area design to meet DARPA requirements. When integrated, MAWED has a dimension size of 72ū94ū71 cm3 (LūWūH) with energy consumption of 74.6 Wh to generation 1 L potable water at 40 ░F 30% RH. The energy consumption decreases with increasing temperature and humidity. Its straightforward design makes it a plug-and-play system, eliminating the need for complex sensors and control systems. Water is captured through diffusion and capillary effect, preventing contamination from the ambience and the capturing process. Additional water purification components eliminate potential biological contamination from long-term storage. Furthermore, the mineralization filter enhances the water's health by adding minerals.ĀIn Phase I, CL will fabricate a small prototype for the proof of concept. In Phase II, a high-fidelity full-size prototype will be prepared and demonstrated at DARPA facilities.

SBIR

Phase I

2025

DOD

DARPA

NGS based metagenomic screening of ocular infections

Amount: $803,560 Topic: NEI

Project Summary/Abstract: The project objective is to develop an organism-agnostic deep sequencing-based diagnosis of ocular infectious disease from microliter-sized biopsies in less than 24 hours and for less than $1000. Current diagnostic approach relies on bacterial and fungal cultures that are time-consuming (~2-3 days) and often leads to the overuse of broad-spectrum antibiotics. In Phase I, we successfully developed and validated the EYE-Path™ system, demonstrating an integrated Scalable Metagenomics Alignment Research Tool (SMART) with an automated DNA extraction system for sample preparation. This system achieved a low limit of detection (104 cells/mL) and a turnaround time of <3 hours for bacterial infections. In Phase II, we plan to optimize the adaptive sequencing software for the SMART Adapt algorithm, validate the system in a multi-site clinical study (University of California, Los Angeles and University of Washington) in patients with corneal ulcer and suspected endophthalmitis, validate the system as a CLIA ready test and initiate a pre-submission meeting with the FDA to determine the appropriate regulatory strategy for eye-PATH to be considered as a CLIA waived in vitro-diagnostic device. The success completion of this project could significantly impact ocular infection diagnosis and treatment planning, with broader applications in point-of-care devices and non-ophthalmic diagnostics, helping to combat antimicrobial resistance.

STTR

Phase II

2024

HHS

NIH

Microorganisms Genome Enrichment and Amplification Sequencing (MGEAS)

Amount: $846,741 Topic: S13

Recent evidence shows that the cleanrooms of Jet Propulsion Laboratory environments, such as floors and hardware surfaces, could harbor various microorganisms, and a comprehensive metagenomics framework to characterize organisms relevant to planetary protection is needed. Current metagenomics practices for microbe detection in low biomass samples generally do not fit well with NASA needs, due to high requirements in DNA concentration, small sample processing volumes, variability, and high predictive errors. MGEAS addresses these issues with three modules (1) A sampling or filtration unit that process larger volumes of input solutions, (2) DNA preparations, enrichment, and amplifications followed by NGS sequencing, (3) Bioinformatics pipeline optimization for reads classification and genome assembly. As part of the phase I project ChromoLogic i) successfully evaluated two state-of-the-art genome amplification or enrichment techniques for NGS library preparation. ii) optimized kmers and various bioinformatics parameters for microbial taxa classification based on raw reads and iii) provided taxa reports for JPL environmental samples (wipes and swabs) and identified taxa with radiation, disinfectant resistance. In Phase II we propose to combine our achievements with a) the novel use of SMART accessory blocks for lab-work automations, and various techniques to improve nucleic acids yield and assay repeatability, b) state of the art DNA preparations, enrichment and amplifications followed by NGS sequencing, and c) Bioinformatics pipeline optimization for reads classification, genome assembly and adjacent DNA linked reads sequencing (Hi-C) for radiation/disinfectant resistant elements origin tracing (in species and environments). We will also expand our statistical modeling tests to improve accuracy and sensitivity of assays to fit NASA needs and we will build interactive software visualization tools for easier user navigation of taxa data and sample statistics.

SBIR

Phase II

2024

NASA

Membrane Contactor based CO2 Absorbing Module (MC-CAM)

Amount: $999,929 Topic: N222-120

In order to meet NavyÆs need, ChromoLogic LLC (CL) proposes to develop a Membrane Contactor based CO2 Absorbing Module (MC-CAM) to maintain CO2 concentration of CCR in a safe range (<0.4%). The expected outcome is that MC-CAM system will be integrated smoothly into the existing SCUBA systems providing endurance for over 10 hours. The innovative microstructure, high surface area to package volume ratio, and novel catalyst application enable the design to be compacted to at least 60% of the commercial canisters. The MC-CAM is ruggedized and reusable, primarily based on physical absorption, and designed to protect divers from hypercapnia without any preventive maintenance. The proposed concept has been validated in Phase I and a high-fidelity full-size prototype will be fabricated and demonstrated at Navy facility.

SBIR

Phase II

2024

DOD

NAVY

Rapid, Portable, Surface Texture Based Component Classifier (RAPSTEC) System

Amount: $1,699,887 Topic: DMEA192-002

In order to address these urgent DOD needs, ChromoLogic LLC (CLL) has developed (TRL 6) a Rapid, portable, surface texture based component classifier (RAPSTEC) system that will rely on a machine learning based algorithm to instantly identify a) if a microelectronic component has been re-marked, which is the most common form of microelectronic counterfeiting and/or b) if the component is a clone that was not produced by the original component manufacturer (OCM) and c) create a virtual tag (vTag®) for each component extracted from a PCB so that it can be accurately be re-populated. RAPSTEC leverages the fact that all components, at the micrometer scale, have unique and random surface texture that is intrinsic, immutable, unforgeable and covert. The surface texture of a component, while completely random and unique to the part itself, also represents the manufacturing process (such as the injection mold or polishing technique) that was used to produce the part. These features, because they are at a micrometer scale, cannot be replicated. We have exploited this fundamental fact of nature and developed a range of commercial products based on our patented (Characterization of a Physical Object based on its Surface Roughness, US 10,341,555) hardware platform that uses surface texture to a) uniquely fingerprint a component and/or b) determine if a components surface has been modified. These products are available through our wholly owned subsidiary, Covisus Inc. (www.covisus.com).

SBIR

Phase II

2024

DOD

DMEA

SBIR Topic 134: Alternatives to Benzathine Penicillin for Treatment of Syphilis

Amount: $299,914 Topic: 134

Syphilis is a sexually transmitted disease caused by T. pallidum. The WHO estimates that 7.1 million persons aged 15-49 acquired syphilis in 2020. Benzathine penicillin (BPG) is the only CDC recommended treatment for syphilis. However, recently shortages of this medicine have been reported worldwide. In addition, BPG is given intramuscularly by injection, which makes it difficult to be administered in countries or regions where proper medical facilities or qualified personnel are not available. To address this, ChromoLogic LCC will develop the Lipophilic Conjugates of Tetracycline as Alternatives to Penicillin G for Syphilis Treatment (LC-TAPS). The LC-TAPS are designed to exhibit improved pharmacokinetics and biodistribution compared to tetracyclines drugs. The minimal inhibitory concentration (MIC) for T. pallidum treated with these three LC-TAPS compounds developed will be determined. It is expected that LC-TAPS will have lower MIC values for T. pallidum compared to tetracyclines. The toxicity of the three LC-TAPS toward the host rabbit cells will be also evaluated. The fluorescent properties of LC-TAPS will be utilized to determine their localization, their cellular uptake and biodistribution in human and rabbit cells. These studies will determine the affinity of LC-TAPS antibiotics for these cells.

SBIR

Phase I

2024

HHS

NIH

PHASE I AWARD - AN ORGAN-ON-VASCULARNET MODEL FOR IN VITRO EVALUATION OF RADIATION AND DRUG THERAPIES

Amount: $399,975 Topic: 446

There is an urgent need for near physiological organ-on-chip models that can replace testing in animals for human drug development. The Organ-on-VascularNet platform is a 3D organoid tissue model with selfassembled vascular networks that enables pharmaceutical testing in both normal and malignant tissues. Organ-on-VascularNet models will be exposed to a combination of x-ray irradiation and interferon â (IFN-â) treatment, and the cellular and molecular responses will be compared to the outcomes observed in vivo. We expect that the Organ-on-VascularNet model will allow for the near-physiological interactions of components of the circulating immune system with the resident tissue, which characterize the responses observed in vivo. Thus, IFN-â treatment should protect normal intestinal tissue for radiation-induced damage and should sensitize tumors to immune checkpoint inhibitor therapy. Successful recapitulation of the in vivo responses suggests a role for the Organ-on-VascarNet model in drug development. We will discuss the potential of this technology with the FDA under their Drug Development Tool (DDT) and Innovative Science and Technology Approaches for New Drugs (ISTAND) programs.

SBIR

Phase I

2024

HHS

NIH

Membrane Contactor based CO2 Absorbing Module (MC-CAM)

Amount: $239,931 Topic: N222-120

In order to meet Navy’s need, ChromoLogic LLC (CL) proposes to develop a Membrane Contactor based CO2 Absorbing Module (MC-CAM) to timely remove CO2 maintain CO2 concentration of CCR in a safe range (<0.2%). It’s anticipated that MC-CAM system will be smoothly integrated to the current military SCUBA rebreathers providing endurance for over 10 hours. The end product will become standard CO2 scrubbing solution for all underwater operations. The high ratio of surface area to package volume, innovative microstructure, and application of novel catalyst enable the entire design to be compacted at least to 60% of the commercial canisters. Mainly based on physical absorption, the ruggedized MC-CAM is reusable and is supposed to protect divers from hypercapnia without any prevention maintenance. In Phase I, CL will fabricate a small prototype for the proof of concept. In Phase II, a high fidelity full size prototype will be prepared and demonstrated at Navy facilities.

SBIR

Phase I

2023

DOD

NAVY

CRISPR-based Tropical Infection Diagnostics

Amount: $299,937 Topic: 119

To develop a device for the detection of malaria.

SBIR

Phase I

2023

HHS

NIH

Aerophilic‐electrode‐based Membrane Free Electrolyzer (AMeFE)

Amount: $549,993 Topic: CBD203-002

In order to address DoD’s urgent need for decentralized generation of hydrogen peroxide for decontamination on remote sites, ChromoLogic LLC (CL) proposes to develop an aerophilic-electrode-based membrane free electrolyzer (AMeFE) as a light-weight, energy saving, and high efficiency H2O2 generator to support application of vaporized hydrogen peroxide. Unlike the regular electrolysis reactors, AMeFE will boost H2O2 productivity with deliberately design carbon-based catalytic electrodes for 2e- WOR and 2e- ORR simultaneously. With assistance of solid electrolyte, contaminant-free H2O2 solution is supposed to be directly generated in AMeFE without application of any post-treatment (e.g. purification or separation process) on the product. According to the preliminary test result and estimation, the AMeFE device is capable of producing 0.2L 35 wt% H2O2 solution per hour without containing any potential hazards.

SBIR

Phase II

2023

DOD

CBD